Insiders Blueprint Medicines Corporation

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-08 EDT			5-day change	1st Jan Change
108.8 ^USD	+0.21%		+14.67%	+17.93%

05-06	Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing	MT
05-06	Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating	MT

Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing	05-06	MT
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	03-22	MT
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	03-01	MT
Blueprint Medicines Insider Sold Shares Worth $395,350, According to a Recent SEC Filing	12-13	MT
Blueprint Medicines Insider Sold Shares Worth $375,000, According to a Recent SEC Filing	12-11	MT
Blueprint Medicines Insider Sold Shares Worth $352,750, According to a Recent SEC Filing	12-04	MT
Blueprint Medicines Insider Sold Shares Worth $1,012,690, According to a Recent SEC Filing	11-28	MT
Blueprint Medicines Insider Sold Shares Worth $601,980, According to a Recent SEC Filing	11-03	MT
Blueprint Medicines Insider Sold Shares Worth $181,138, According to a Recent SEC Filing	23-10-05	MT
Blueprint Medicines Insider Sold Shares Worth $1,244,030, According to a Recent SEC Filing	23-09-29	MT
Insider Sell: Blueprint Medicines	23-08-29	MT
Blueprint Medicines Corporation Announces Board Changes	23-01-06	CI
Insider Sell: Blueprint Medicines	22-12-08	MT
Insider Sell: Blueprint Medicines	22-08-23	MT
Insider Sell: Blueprint Medicines	22-08-19	MT
Blueprint Medicines Appoints Habib Dable to its Board of Directors	22-06-23	CI
Insider Sell: Blueprint Medicines	22-06-08	MT
Insider Sell: Blueprint Medicines	22-05-18	MT
Insider Sell: Blueprint Medicines	22-03-18	MT
Insider Sell: Blueprint Medicines	22-03-09	MT

No results for this search